1-8 of 8
Alessandra Di Bacco
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models

Katharine Ellwood-Yen, Heike Keilhack, Kaiko Kunii, Brian Dolinski, Yamicia Connor, Kun Hu, Kumiko Nagashima, Erin O'Hare, Yusuf Erkul, Alessandra Di Bacco, Diana Gargano, Nirah H. Shomer, Minilik Angagaw, Erica Leccese, Paula Andrade, Melissa Hurd, Myung K. Shin, Thomas F. Vogt, Alan Northrup, Ekaterina V. Bobkova, Shailaja Kasibhatla, Roderick T. Bronson, Martin L. Scott, Giulio Draetta, Victoria Richon, Nancy Kohl, Peter Blume-Jensen, Jannik N. Andersen, Manfred Kraus
Journal: Cancer Research
Cancer Res (2011) 71 (8): 3052–3065.
https://doi.org/10.1158/0008-5472.CAN-10-2282
Published: 13 April 2011
View article titled, PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Open the PDF for PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models in another window
Includes: Supplementary data
Journal Articles

Abstract 5560: Biomarker Discovery and Pathway Mapping using Differential Phosphoprofiling of PI3K-Pathway Inhibitors: PRAS40 Correlates with AKT Activation, but not PTEN Expression in Lung and Breast Cancer

Cloud P. Paweletz, Jannik Andersen, Sriram Sathyanarayanan, Alessandra Di Bacco, An Chi, Theresa Zhang, Chen Albert, Igor Feldman, Manfred Kraus, Bethany Lynch, John Rush, Peter Blume-Jensen, Ronald C. Hendrickson
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5560.
https://doi.org/10.1158/1538-7445.AM10-5560
Published: 15 April 2010
View article titled, Abstract 5560: Biomarker Discovery and Pathway Mapping using Differential Phosphoprofiling of PI3K-Pathway Inhibitors: PRAS40 Correlates with AKT Activation, but not PTEN Expression in Lung and Breast Cancer
Journal Articles

Abstract 284: FGFR2 is required for growth and survival in a rare subset of FGFR2 amplified colorectal cancer

Anjili Mathur, Lenora Davis, Alessandra Di Bacco, Adi Gazdar, Bart Lutterbach
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 284.
https://doi.org/10.1158/1538-7445.AM10-284
Published: 15 April 2010
View article titled, Abstract 284: FGFR2 is required for growth and survival in a rare subset of <em>FGFR2</em> amplified colorectal cancer
Journal Articles

Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models

Marlene C. Artime, Samuel Blackman, Scot Ebbinghaus, Ray Lee, Alessandra Di Bacco, Diana Gargano, Theresa Zhang, Nagaraja Muniappa, Punam Sandhu, Gail Gitzlaff, Cynthia Chavez-Eng, James Watters, Melissa Chenard, Edwin Clark, Christopher Winter, Brian B. Haines
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 3478.
https://doi.org/10.1158/1538-7445.AM10-3478
Published: 15 April 2010
View article titled, Abstract 3478: PI3K suppression by the mTOR inhibitor ridaforolimus and the AKT inhibitor MK-2206 is associated with enhanced anti-tumor activity and hyperglycemia in preclinical models
Journal Articles

Abstract #2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity

Sriram Sathyanarayanan, Sharda Jha, Richard Klinghoffer, Youyuan Xu, Mark Bittinger, Jason Frazier, Alessandra Di Bacco, Michael Chastain, Astrid Kral, Nancy Kohl, Brian Haines, Katharine Yen, Shailaja Kasibhatla, Christopher Winter
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2809.
Published: 01 May 2009
View article titled, Abstract #2809: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity
Journal Articles

Abstract #1887: The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer

Brian Haines, Mark Bittinger, Melissa Chenard, Marlene Artime, Amy Guertin, Shavonne Howard, Weisheng Zhang, Raquel Sevilla, Christopher Ware, Diana Gargano, Aimee Michael, Andreas Harsch, Alessandra Di Bacco, Theresa Zhang, Brian Roberts, William Arthur, Nancy Kohl, Shailaja Kasibhatla, Manfred Lehnert, Scot Ebbinghaus, Winter Christopher
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 1887.
Published: 01 May 2009
View article titled, Abstract #1887: The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer
Journal Articles

Using RNAi to identify modulators of the HIF pathway/hypoxia for cancer

Edyta Tyminski, Cole Liberator, Tom Rush, Theresa Zhang, Chris Winter, Alessandra Di Bacco, Marlene Artime, Brian Haines, Steve Bartz, Zhan Zhang, Aaron Chang, Bin Zhang, Jun Zhu, Marc Ferrer, Raul Lacson, Yaping Liu, Joleen Kajdas, David Ross, Smith Todd, Locco Lou, Ansu Bagchi, Eric Minch, Pam Carroll, Joe Marszalek
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2380.
Published: 01 May 2008
View article titled, Using RNAi to identify modulators of the HIF pathway/hypoxia for cancer
Journal Articles

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

Kaiko Kunii, Lenora Davis, Julie Gorenstein, Harold Hatch, Masakazu Yashiro, Alessandra Di Bacco, Cem Elbi, Bart Lutterbach
Journal: Cancer Research
Cancer Res (2008) 68 (7): 2340–2348.
https://doi.org/10.1158/0008-5472.CAN-07-5229
Published: 01 April 2008
View article titled, <em>FGFR2</em>-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
Open the PDF for <em>FGFR2</em>-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival in another window
Includes: Supplementary data